Hypoxia-inducible factors, hypoxia, and tumor angiogenesis

Current Opinion in Hematology

Volumn 13, Issue 3, 2006, Pages 169-174

  Gruber, Michaela ^a,c   Simon, M Celeste ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Angiogenesis; Hypoxia; Hypoxia inducible factor; Reactive oxygen species; Tumor

Indexed keywords

ANGIOGENIC FACTOR; CELL PROTEIN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR JUND; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ADAPTATION; CANCER; CARCINOGENESIS; DEVELOPMENT; GENE EXPRESSION; GENE MUTATION; GENETIC DAMAGE; HUMAN; HYPOXIA; KIDNEY CARCINOMA; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; REVIEW; THERAPY; TUMOR VASCULARIZATION;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL HYPOXIA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MUTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 33646764243     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/01.moh.0000219663.88409.35     Document Type: Review

References (41)

1. 2 tension. Proc Natl Acad Sci U S A 1995; 92:5510-5514.
2. Wenger RH, Gassmann M. Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem 1997; 378:609-616.
3. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000; 2:423-427.
4. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292:468-472.
5. Makino Y, Cao R, Svensson K, et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001; 414:550-554.
6. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399:271-275.
7. Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000; 275:25733-25741.
8. Kallio PJ, Wilson WJ, O'Brien S, et al. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem 1999; 274:6519-6525.
9. Salceda S, Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions: its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997; 272:22642-22647.
10. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 2000; 19:4298-4309.
11. 2- regulated gene expression. FASEB J 2002; 16:1151-1162.
12. Schmid T, Zhou J, Kohl R, Brune B. p300 relieves p53-evoked transcriptional repression of hypoxia-inducible factor-1 (HIF-1). Biochem J 2004; 380 (part 1):289-295.
13. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000; 14:34-44.
14. Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000; 14:391-396.
15. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003; 1:E83.
16. Kondo K, Klco J, Nakamura E, et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002; 1:237-246.
17. Haase VH. The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting. Semin Cell Dev Biol 2005; 16:564-574.
18. Gnarra JR, Ward JM, Porter FD, et al. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A 1997; 94:9102-9107.
19. Rankin EB, Higgins DF, Walisser JA, et al. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol 2005; 25:3163-3172. This paper shows that the liver hemangiomas formed by loss of pVhl can be rescued when Arnt is removed, but not by deleting Hif-1α.
20. Raval RR, Lau KW, Tran MG, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005; 25:5675-5686. This study investigates the specific functions of HIF-1α and HIF-2α in RCC. It describes the tumor-promoting, proliferative function of HIF-2α and the proapoptotic role HIF-1α plays in this specific tumor.
21. Mack FA, Rathmell WK, Arsham AM, et al. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 2003; 3:75-88.
22. Mack FA, Patel JH, Biju MP, et al. Decreased growth of Vhl-/- fibrosarcomas is associated with elevated levels of cyclin kinase inhibitors p21 and p27. Mol Cell Biol 2005; 25:4565-4578. The authors report that loss of the tumor suppressor Vhl is enough to dysregulate HIF degradation but not sufficient for tumor development, suggesting that further mutations are necessary for a malignant phenotype.
23. Koshiji M, Kageyama Y, Pete EA, et al. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 2004; 23:1949-1956.
24. Covello KL, Simon MC, Keith B. Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Res 2005; 65:2277-2286.
25. Ryan HE, Poloni M, McNulty W, et al. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 2000; 60:4010-4015.
26. Smith K, Gunaratnam L, Morley M, et al. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res 2005; 65:5221-5230. This study reports that HIF-2α specifically promotes tumorigenesis by activating the TGF-α/EGFR pathway.
27. Sun X, Liu M, Wei Y, et al. Overexpression of von Hippel-Lindau tumor suppressor protein and antisense HIF-1alpha eradicates gliomas. Cancer Gene Ther 2005 Oct 7 [Epub ahead of print] The authors show that overexpressing pVHL in gliomas with wild-type pVHL leads to a reduction in HIF-1α levels and a decrease in tumor growth.
28. Acker T, Diez-Juan A, Aragones J, et al. Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell 2005; 8:131-141. This report provides evidence that HIF-2α acts as a tumor suppressor when overexpressed in glioma tumors. The expression of an HIF inhibitor accelerates the growth of gliomas.
29. Mizukami Y, Jo WS, Duerr EM, et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 2005; 11:992-997. This report shows that HIF-1α knockdown leads to smaller tumors formed after subcutaneous injections; however, angiogenesis is only partially blocked. This is due to induced expression of interleukin-8.
30. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 1998; 17:3005-3015.
31. Iyer NV, Kotch LE, Agani F, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998; 12:149-162.
32. Peng J, Zhang L, Drysdale L, Fong GH. The transcription factor EPAS-1/ hypoxia-inducible factor 2alpha plays an important role in vascular remodelling. Proc Natl Acad Sci U S A 2000; 97:8386-8391.
33. Maltepe E, Schmidt JV, Baunoch D, et al. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 1997; 386:403-407.
34. Licht AH, Muller-Holtkamp F, Flamme I, Breier G. Inhibition of hypoxia-inducible factor activity in endothelial cells disrupts embryonic cardiovascular development. Blood 2006; 107:584-590. [Epub ahead of print] This paper reports an endothelial cell intrinsic function for HIF-α.
35. Tang N, Wang L, Esko J, et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004; 6:485-495.
36. Maranchie JK, Zhan Y. Nox4 is critical for hypoxia-inducible factor 2-alpha transcriptional activity in von Hippel-Lindau-deficient renal cell carcinoma. Cancer Res 2005; 65:9190-9193.
37. Ozer A, Wu LC, Bruick RK. The candidate tumor suppressor ING4 represses activation of the hypoxia inducible factor (HIF). Proc Natl Acad Sci USA 2005; 102:7481-7486.
38. Gerald D, Berra E, Frapart YM, et al. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 2004; 118:781-794.
39. Mansfield KD, Guzy RD, Pan Y, et al. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab 2005; 1:393-399. Describes the important role of mitochondrial ROS in stabilizing HIF-α under hypoxia.
40. Guzy RD, Hoyos B, Robin E, et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 2005; 1:401-408. Describes the important role of mitochondrial ROS in stabilizing HIF-α under hypoxia.
41. Brunelle JK, Bell EL, Quesada NM, et al. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab 2005; 1:409-414. Describes the important role of mitochondrial ROS in stabilizing HIF-α under hypoxia.